Title
Category
Credits
Event date
Cost
  • AMA PRA Category 1 Credit™
  • Participation
$39.00
*This activity is free of charge to those registered for ANA2021. Please click continue to access the content. Please contact us if you are prompted to pay the fee and were registered for the meeting.*
  • AMA PRA Category 1 Credit™
  • Participation
$39.00
*This activity is free of charge to those registered for ANA2021. Please click continue to access the content. Please contact us if you are prompted to pay the fee and were registered for the meeting.*
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
This is the second event for "Creating a successful research program: Combining great mentorship with compelling science and building a diverse and inclusive research environment," a series of presentations with interactive discussions brought to you through a partnership between the National Institute of Neurological Disorders and Stroke (NINDS) and the American Neurological Association (ANA).Speaker: Louise D. McCullough, MD, PhD
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this 19-minute presentation, Dr. Deanna Saylor Assistant Professor of Neurology, Director, Hopkins Global Neurology Program at the Johns Hopkins University School of Medicine and currently on assignment in Zambia, talks us through how the current pandemic environment elevates the importance of partnering globally to learn from each other, acting globally by taking assignments in areas in most need, and thinking globally by considering where global perspectives may improve research.
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
During this 36-minute video, Dr. Thanh Nguyen takes us through the origin of COVID-19 and its impact on stroke care - both for patients and clinicians. Note: Dr. Nguyen obtained permission to use the images used in this presentation and offered disclosures at the start of the presentation. 
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this 19-minute video, Dr. Jee Bang provides an overview of the current state of research and therapy for Huntington Disease. 
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this 12-minute video, Dr. Basil Darras, Professor of Neurology at Boston Children’s Hospital and Harvard Medical School, introduces the learner to spinal muscular atrophy (SMA), the number one genetic cause of death in infants. SMA is a genetic disorder characterized by degeneration and loss of motor neurons in the anterior horns of the spinal cord and brain stem of children and adults, with limited involvement of peripheral organs in severely affected patients. What are the extra-neuronal phenotypes of SMA in humans and animal models? Part 1 of 2. 
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In part 2 of this series, Dr. Crystal Yeo, Assistant Professor at LKC School of Medicine, Associated Staff at Boston Children’s Hospital, joint Medical Director at EDDC and Group Leader at IMCB, continues on to review the changing therapeutic landscape for spinal muscular atrophy (SMA), the extra-neuronal expression of survival motor neuron (SMN) protein, and motor neuron cell-non-autonomous rescue in animal models. What are the clinical implications for patients treated with SMN protein augmenting interventions?
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Hosted by Drs. Jason Hinman & Bhooma Aravamuthan, and featuring panelists Drs. David Holtzman, Rachel Salas, and Kathrin LaFaver, this 60 minute event focused on the spectrum of professional networking featuring an introduction to how to network at conferences in person and how to network on Twitter and Facebook, followed by suggestions from everyone via a panel Q and A on how one might network at virtual meetings, including the virtual ANA meeting in 2020. 
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
During this 60-minute session, Dr. John Ciotti hosted Drs. Elena Grebenciucova, Scott Newsome, and Brandon Moss discussing implications of disease-modifying therapies for MS on COVID-19 susceptibility/severity, starting/switching therapies, vaccine responses, and other clinical considerations.

Pages